|
|
|
|
| LEADER |
02114nam a2200325 u 4500 |
| 001 |
EB001839759 |
| 003 |
EBX01000000000000001003748 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 020 |
|
|
|a 9789241508193
|
| 245 |
0 |
0 |
|a Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents, and children
|h Elektronische Ressource
|b recommendations for a public health approach : December 2014 supplement to the 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
|
| 260 |
|
|
|a Geneva
|b World Health Organization
|c 2014, [2014]
|
| 300 |
|
|
|a 1 PDF file (44 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Anti-Retroviral Agents / therapeutic use
|
| 653 |
|
|
|a Adult
|
| 653 |
|
|
|a Child
|
| 653 |
|
|
|a HIV Infections / prevention & control
|
| 653 |
|
|
|a HIV Infections / drug therapy
|
| 653 |
|
|
|a Adolescent
|
| 653 |
|
|
|a Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
|
| 710 |
2 |
|
|a World Health Organization
|
| 740 |
0 |
2 |
|a Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 500 |
|
|
|a Title from PDF title page
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK298964
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a These guidelines provide new recommendations and updates to previous recommendations outlined in Chapter 5 (ARV drugs for HIV prevention) and Chapter 8 (Managing common coinfections and comorbidities) of the 2013 consolidated ARV guidelines. Recommendations are organized along the continuum of care. These guidelines reflect important advances in the use of ARV drugs to prevent HIV with more simplified approaches to post-exposure prophylaxis and simplifying the indications on the use of co-trimoxazole to prevent opportunistic infections, bacterial infections and malaria
|